Healthcare provider profile · identity verified

Michael Deanda, MD

Family Practice · LA VERNE, CA · NPI 1750381711

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	680	212
Amlodipine Besylate	Amlodipine Besylate	298	97
Losartan Potassium	Losartan Potassium	257	80
Metformin Hcl	Metformin Hcl	255	80
Levothyroxine Sodium	Levothyroxine Sodium	212	65
Rosuvastatin Calcium	Rosuvastatin Calcium	168	56
Omeprazole	Omeprazole	162	50
Lisinopril	Lisinopril	158	49
Tamsulosin Hcl	Tamsulosin Hcl	137	43
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	120	24
Albuterol Sulfate Hfa	Albuterol Sulfate	107	28
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	107	30
Simvastatin	Simvastatin	107	32
Hydrochlorothiazide	Hydrochlorothiazide	103	34
Atenolol	Atenolol	98	27
Benazepril Hcl	Benazepril Hcl	97	23
Jardiance	Empagliflozin	96	24
Metoprolol Succinate	Metoprolol Succinate	95	30
Eliquis	Apixaban	89	26
Gabapentin	Gabapentin	87	29
Escitalopram Oxalate	Escitalopram Oxalate	84	24
Potassium Chloride	Potassium Chloride	83	22
Pantoprazole Sodium	Pantoprazole Sodium	75	24
Glimepiride	Glimepiride	73	23
Trazodone Hcl	Trazodone Hcl	71	18
Alprazolam	Alprazolam	68	17
Triamcinolone Acetonide	Triamcinolone Acetonide	68	33
Furosemide	Furosemide	67	26
Famotidine	Famotidine	64	24
Alendronate Sodium	Alendronate Sodium	62	23
Montelukast Sodium	Montelukast Sodium	60	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	58	14
Metoprolol Tartrate	Metoprolol Tartrate	56	16
Fluticasone Propionate	Fluticasone Propionate	55	32
Lorazepam	Lorazepam	51	16
Trulicity	Dulaglutide	50	suppressed
Carvedilol	Carvedilol	49	16
Diclofenac Sodium	Diclofenac Sodium	49	suppressed
Mirtazapine	Mirtazapine	48	16
Tramadol Hcl	Tramadol Hcl	47	11
Clonazepam	Clonazepam	44	11
Celecoxib	Celecoxib	41	18
Meloxicam	Meloxicam	41	12
Nystatin	Nystatin	41	13
Pravastatin Sodium	Pravastatin Sodium	38	13
Allopurinol	Allopurinol	36	suppressed
Finasteride	Finasteride	36	14
Donepezil Hcl	Donepezil Hcl	35	14
Ozempic	Semaglutide	35	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	35	suppressed
Sertraline Hcl	Sertraline Hcl	34	12
Zolpidem Tartrate	Zolpidem Tartrate	33	suppressed
Memantine Hcl	Memantine Hcl	31	suppressed
Bupropion Xl	Bupropion Hcl	29	11
Xarelto	Rivaroxaban	28	suppressed
Citalopram Hbr	Citalopram Hydrobromide	27	suppressed
Duloxetine Hcl	Duloxetine Hcl	27	suppressed
Ezetimibe	Ezetimibe	27	12
Telmisartan	Telmisartan	27	suppressed
Lovastatin	Lovastatin	26	suppressed
Naproxen	Naproxen	26	suppressed
Farxiga	Dapagliflozin Propanediol	25	suppressed
Spironolactone	Spironolactone	25	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	24	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Diclofenac Potassium	Diclofenac Potassium	23	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	23	suppressed
Synthroid	Levothyroxine Sodium	22	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Glipizide	Glipizide	21	suppressed
Lidocaine	Lidocaine	21	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	20	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	19
Ondansetron Hcl	Ondansetron Hcl	19	11
Symbicort	Budesonide/Formoterol Fumarate	19	suppressed
Azelastine Hcl	Azelastine Hcl	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Prednisone	Prednisone	17	12
Terazosin Hcl	Terazosin Hcl	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Topiramate	Topiramate	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Apidra Solostar	Insulin Glulisine	15	suppressed
Azithromycin	Azithromycin	15	15
Januvia	Sitagliptin Phosphate	15	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	15	suppressed
Sildenafil Citrate	Sildenafil Citrate	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	14	suppressed
Baclofen	Baclofen	13	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	13	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	13	suppressed
Rybelsus	Semaglutide	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Indapamide	Indapamide	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	12
Warfarin Sodium	Warfarin Sodium	12	suppressed
Carisoprodol	Carisoprodol	11	suppressed
Linzess	Linaclotide	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Spiriva Handihaler	Tiotropium Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error